Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes
Abstract Aims/Introduction To assess whether the sodium–glucose cotransporter 2 inhibitor, henagliflozin, improves cognitive impairment in patients with type 2 diabetes. Materials and Methods We carried out a prospective study on 290 patients with type 2 diabetes and cognitive impairment. Montreal C...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850285053066608640 |
|---|---|
| author | Shujun Zhang Fen Wang Lei Xie Jialu Xu Xiaoqing Song Jing Tao Juan Chen Delin Ma Xuefeng Yu Xiaoli Shi Yan Yang |
| author_facet | Shujun Zhang Fen Wang Lei Xie Jialu Xu Xiaoqing Song Jing Tao Juan Chen Delin Ma Xuefeng Yu Xiaoli Shi Yan Yang |
| author_sort | Shujun Zhang |
| collection | DOAJ |
| description | Abstract Aims/Introduction To assess whether the sodium–glucose cotransporter 2 inhibitor, henagliflozin, improves cognitive impairment in patients with type 2 diabetes. Materials and Methods We carried out a prospective study on 290 patients with type 2 diabetes and cognitive impairment. Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels were used to assess cognition. The association between henagliflozin use and changes in cognition was examined using multivariable logistic regression analysis. Results Montreal Cognitive Assessment scores at enrollment and after 6 months were 21 (interquartile range [IQR]19–23) versus 22 (IQR 20–25; P < 0.0001) in all patients, 21 (IQR 19–23) versus 24 (IQR 22–26; P < 0.0001) in the henagliflozin group and 21 (IQR 19–22) versus 21 (IQR 19–23; P > 0.05) in the non‐sodium–glucose cotransporter 2 inhibitor group. Logistic regression analysis showed that henagliflozin treatment was associated with Montreal Cognitive Assessment score improvement independent of potential confounders (odds ratio [OR] 3.670, 95% confidence interval [CI] 2.224–6.056, P < 0.0001). Additionally, plasma phosphorylated tau181 levels significantly decreased at 6‐month follow up in all patients (OR 11.5, 95% CI 9.9–13.7 vs OR 10.1, 95% CI 7.8–12.9, P < 0.0001) and in the henagliflozin group (OR 11.5, 95% CI 10.3–13.0 vs OR 9.2, 95% CI 7.1–10.7, P < 0.0001), but not in the non‐sodium–glucose cotransporter 2 inhibitor group. Henagliflozin treatment was independently associated with decreased phosphorylated tau181 levels (OR 3.670, 95% CI 1.598–4.213, P < 0.0001). Conclusions Henagliflozin treatment was independently associated with improvements in Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels, indicating significant beneficial effects on cognitive impairment in patients with type 2 diabetes. |
| format | Article |
| id | doaj-art-322bd7944a9b43058ec41cf8c47d84d3 |
| institution | OA Journals |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-322bd7944a9b43058ec41cf8c47d84d32025-08-20T01:47:25ZengWileyJournal of Diabetes Investigation2040-11162040-11242024-11-0115111596160310.1111/jdi.14306Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetesShujun Zhang0Fen Wang1Lei Xie2Jialu Xu3Xiaoqing Song4Jing Tao5Juan Chen6Delin Ma7Xuefeng Yu8Xiaoli Shi9Yan Yang10Department of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Neurosurgery, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaDepartment of Endocrinology, Tongji Medical College, Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei Province ChinaAbstract Aims/Introduction To assess whether the sodium–glucose cotransporter 2 inhibitor, henagliflozin, improves cognitive impairment in patients with type 2 diabetes. Materials and Methods We carried out a prospective study on 290 patients with type 2 diabetes and cognitive impairment. Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels were used to assess cognition. The association between henagliflozin use and changes in cognition was examined using multivariable logistic regression analysis. Results Montreal Cognitive Assessment scores at enrollment and after 6 months were 21 (interquartile range [IQR]19–23) versus 22 (IQR 20–25; P < 0.0001) in all patients, 21 (IQR 19–23) versus 24 (IQR 22–26; P < 0.0001) in the henagliflozin group and 21 (IQR 19–22) versus 21 (IQR 19–23; P > 0.05) in the non‐sodium–glucose cotransporter 2 inhibitor group. Logistic regression analysis showed that henagliflozin treatment was associated with Montreal Cognitive Assessment score improvement independent of potential confounders (odds ratio [OR] 3.670, 95% confidence interval [CI] 2.224–6.056, P < 0.0001). Additionally, plasma phosphorylated tau181 levels significantly decreased at 6‐month follow up in all patients (OR 11.5, 95% CI 9.9–13.7 vs OR 10.1, 95% CI 7.8–12.9, P < 0.0001) and in the henagliflozin group (OR 11.5, 95% CI 10.3–13.0 vs OR 9.2, 95% CI 7.1–10.7, P < 0.0001), but not in the non‐sodium–glucose cotransporter 2 inhibitor group. Henagliflozin treatment was independently associated with decreased phosphorylated tau181 levels (OR 3.670, 95% CI 1.598–4.213, P < 0.0001). Conclusions Henagliflozin treatment was independently associated with improvements in Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels, indicating significant beneficial effects on cognitive impairment in patients with type 2 diabetes.https://doi.org/10.1111/jdi.14306Cognitive impairmentHenagliflozinType 2 diabetes |
| spellingShingle | Shujun Zhang Fen Wang Lei Xie Jialu Xu Xiaoqing Song Jing Tao Juan Chen Delin Ma Xuefeng Yu Xiaoli Shi Yan Yang Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes Journal of Diabetes Investigation Cognitive impairment Henagliflozin Type 2 diabetes |
| title | Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| title_full | Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| title_fullStr | Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| title_full_unstemmed | Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| title_short | Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| title_sort | sodium glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes |
| topic | Cognitive impairment Henagliflozin Type 2 diabetes |
| url | https://doi.org/10.1111/jdi.14306 |
| work_keys_str_mv | AT shujunzhang sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT fenwang sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT leixie sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT jialuxu sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT xiaoqingsong sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT jingtao sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT juanchen sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT delinma sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT xuefengyu sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT xiaolishi sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes AT yanyang sodiumglucosecotransporter2inhibitionthroughhenagliflozinamelioratescognitiveimpairmentinpatientswithtype2diabetes |